{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T18:14:51Z","timestamp":1790273691163,"version":"4.1.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T00:00:00Z","timestamp":1696377600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"crossref","award":["2021R1A2C301335711"],"award-info":[{"award-number":["2021R1A2C301335711"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"crossref"}]},{"name":"BK21 program"},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["RS-2023-00272063"],"award-info":[{"award-number":["RS-2023-00272063"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Prostate cancer is the most prevalent cancer in men worldwide and is promoted by the sex hormone androgen. Expression of androgen from the testis can be significantly reduced through castration. However, as most prostate cancer patients acquire castration resistance, additional therapeutic solutions are necessary. Although anti-androgens, such as enzalutamide, have been used to treat castration-resistant prostate cancer (CRPC), enzalutamide-resistant CRPC (Enz-resistant CRPC) has emerged. Therefore, development of novel treatments for Enz-resistant CRPC is urgent. In this study, we found a novel anti-androgen called pinostilbene through screening with a GAL4-transactivation assay. We confirmed that pinostilbene directly binds to androgen receptor (AR) and inhibits its activation and translocalization. Pinostilbene treatment also reduced the protein level and downstream gene expression of AR. Furthermore, pinostilbene reduced the protein level of AR variant 7 in the Enz-resistant prostate cancer cell line 22Rv1 and inhibited cell viability and proliferation. Our results suggest that pinostilbene has the potential to treat Enz-resistant CRPC.<\/jats:p>","DOI":"10.1038\/s41598-023-43561-5","type":"journal-article","created":{"date-parts":[[2023,10,4]],"date-time":"2023-10-04T10:02:08Z","timestamp":1696413728000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pinostilbene inhibits full-length and splice variant of androgen receptor in prostate cancer"],"prefix":"10.1038","volume":"13","author":[{"given":"Won Sik","family":"Shin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seung Hyun","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyung Won","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunje","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyong-Tai","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,4]]},"reference":[{"key":"43561_CR1","unstructured":"Leslie, S. W., Soon-Sutton, T. L., Anu R. I., Sajjad, H. & Siref, L. E. in StatPearls (2023)."},{"key":"43561_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel, R. L., Miller, K. D., Wagle, N. S. & Jemal, A. Cancer statistics, 2023. CA Cancer J. Clin. 73, 17\u201348. https:\/\/doi.org\/10.3322\/caac.21763 (2023).","journal-title":"CA Cancer J. Clin."},{"key":"43561_CR3","first-page":"S260","volume":"20","author":"N Shore","year":"2014","unstructured":"Shore, N. Management of early-stage prostate cancer. Am. J. Manag. Care 20, S260-272 (2014).","journal-title":"Am. J. Manag. Care"},{"key":"43561_CR4","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1007\/s40271-018-0349-x","volume":"12","author":"S Holmstrom","year":"2019","unstructured":"Holmstrom, S. et al. Symptoms and impacts in metastatic castration-resistant prostate cancer: Qualitative findings from patient and physician interviews. Patient 12, 57\u201367. https:\/\/doi.org\/10.1007\/s40271-018-0349-x (2019).","journal-title":"Patient"},{"key":"43561_CR5","doi-asserted-by":"publisher","first-page":"63","DOI":"10.14740\/wjon1191","volume":"10","author":"P Rawla","year":"2019","unstructured":"Rawla, P. Epidemiology of prostate cancer. World J. Oncol. 10, 63\u201389. https:\/\/doi.org\/10.14740\/wjon1191 (2019).","journal-title":"World J. Oncol."},{"key":"43561_CR6","doi-asserted-by":"publisher","first-page":"e938","DOI":"10.1200\/OP.21.00816","volume":"18","author":"LM Ruppert","year":"2022","unstructured":"Ruppert, L. M. et al. Spine pain and metastatic prostate cancer: Defining the contribution of nonmalignant etiologies. JCO Oncol. Pract. 18, e938\u2013e947. https:\/\/doi.org\/10.1200\/OP.21.00816 (2022).","journal-title":"JCO Oncol. Pract."},{"key":"43561_CR7","first-page":"3","volume":"37","author":"RA Davey","year":"2016","unstructured":"Davey, R. A. & Grossmann, M. Androgen receptor structure, function and biology: From bench to bedside. Clin. Biochem. Rev. 37, 3\u201315 (2016).","journal-title":"Clin. Biochem. Rev."},{"key":"43561_CR8","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1002\/jcb.20228","volume":"93","author":"J Kim","year":"2004","unstructured":"Kim, J. & Coetzee, G. A. Prostate specific antigen gene regulation by androgen receptor. J. Cell Biochem. 93, 233\u2013241. https:\/\/doi.org\/10.1002\/jcb.20228 (2004).","journal-title":"J. Cell Biochem."},{"key":"43561_CR9","first-page":"4180","volume":"59","author":"B Lin","year":"1999","unstructured":"Lin, B. et al. Prostate-localized and androgen-regulated expression of the membrane-bound serine protease TMPRSS2. Cancer Res. 59, 4180\u20134184 (1999).","journal-title":"Cancer Res."},{"key":"43561_CR10","doi-asserted-by":"publisher","first-page":"7110","DOI":"10.1158\/0008-5472.CAN-07-6507","volume":"68","author":"Y Niu","year":"2008","unstructured":"Niu, Y. et al. Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res. 68, 7110\u20137119. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6507 (2008).","journal-title":"Cancer Res."},{"key":"43561_CR11","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1677\/erc.1.00958","volume":"12","author":"TL Veveris-Lowe","year":"2005","unstructured":"Veveris-Lowe, T. L. et al. Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells. Endocr. Relat. Cancer 12, 631\u2013643. https:\/\/doi.org\/10.1677\/erc.1.00958 (2005).","journal-title":"Endocr. Relat. Cancer"},{"key":"43561_CR12","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1056\/NEJM200105033441806","volume":"344","author":"MJ Barry","year":"2001","unstructured":"Barry, M. J. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N. Engl. J. Med. 344, 1373\u20131377. https:\/\/doi.org\/10.1056\/NEJM200105033441806 (2001).","journal-title":"N. Engl. J. Med."},{"key":"43561_CR13","doi-asserted-by":"publisher","first-page":"2949","DOI":"10.1158\/0008-5472.Can-14-3297","volume":"75","author":"CJ Ko","year":"2015","unstructured":"Ko, C. J. et al. Androgen-induced TMPRSS2 activates matriptase and promotes extracellular matrix degradation, prostate cancer cell invasion, tumor growth, and metastasis. Cancer Res. 75, 2949\u20132960. https:\/\/doi.org\/10.1158\/0008-5472.Can-14-3297 (2015).","journal-title":"Cancer Res."},{"key":"43561_CR14","doi-asserted-by":"publisher","first-page":"1310","DOI":"10.1158\/2159-8290.Cd-13-1010","volume":"4","author":"JM Lucas","year":"2014","unstructured":"Lucas, J. M. et al. The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis. Cancer Discov. 4, 1310\u20131325. https:\/\/doi.org\/10.1158\/2159-8290.Cd-13-1010 (2014).","journal-title":"Cancer Discov."},{"key":"43561_CR15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1146\/annurev-med-051418-060357","volume":"71","author":"RJ Auchus","year":"2020","unstructured":"Auchus, R. J. & Sharifi, N. Sex hormones and prostate cancer. Annu. Rev. Med. 71, 33\u201345. https:\/\/doi.org\/10.1146\/annurev-med-051418-060357 (2020).","journal-title":"Annu. Rev. Med."},{"key":"43561_CR16","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3978\/j.issn.2223-4683.2012.07.03","volume":"1","author":"M Namiki","year":"2012","unstructured":"Namiki, M., Ueno, S. & Kitagawa, Y. Role of hormonal therapy for prostate cancer: Perspective from Japanese experiences. Transl. Androl. Urol. 1, 160\u2013172. https:\/\/doi.org\/10.3978\/j.issn.2223-4683.2012.07.03 (2012).","journal-title":"Transl. Androl. Urol."},{"key":"43561_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1001\/jama.294.2.238","volume":"294","author":"N Sharifi","year":"2005","unstructured":"Sharifi, N., Gulley, J. L. & Dahut, W. L. Androgen deprivation therapy for prostate cancer. JAMA 294, 238\u2013244. https:\/\/doi.org\/10.1001\/jama.294.2.238 (2005).","journal-title":"JAMA"},{"key":"43561_CR18","first-page":"1","volume":"14","author":"H Lepor","year":"2012","unstructured":"Lepor, H. & Shore, N. D. LHRH agonists for the treatment of prostate cancer: 2012. Rev. Urol. 14, 1\u201312 (2012).","journal-title":"Rev. Urol."},{"key":"43561_CR19","doi-asserted-by":"publisher","first-page":"157","DOI":"10.4111\/kju.2011.52.3.157","volume":"52","author":"SJ Kim","year":"2011","unstructured":"Kim, S. J. & Kim, S. I. Current treatment strategies for castration-resistant prostate cancer. Korean J. Urol. 52, 157\u2013165. https:\/\/doi.org\/10.4111\/kju.2011.52.3.157 (2011).","journal-title":"Korean J. Urol."},{"key":"43561_CR20","doi-asserted-by":"publisher","first-page":"105506","DOI":"10.1016\/j.jsbmb.2019.105506","volume":"197","author":"M Barnard","year":"2020","unstructured":"Barnard, M., Mostaghel, E. A., Auchus, R. J. & Storbeck, K. H. The role of adrenal derived androgens in castration resistant prostate cancer. J. Steroid Biochem. Mol. Biol. 197, 105506. https:\/\/doi.org\/10.1016\/j.jsbmb.2019.105506 (2020).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"43561_CR21","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/cpt.256","volume":"98","author":"DJ Crona","year":"2015","unstructured":"Crona, D. J., Milowsky, M. I. & Whang, Y. E. Androgen receptor targeting drugs in castration-resistant prostate cancer and mechanisms of resistance. Clin. Pharmacol. Ther. 98, 582\u2013589. https:\/\/doi.org\/10.1002\/cpt.256 (2015).","journal-title":"Clin. Pharmacol. Ther."},{"key":"43561_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.2147\/RRU.S157116","volume":"10","author":"Y Ito","year":"2018","unstructured":"Ito, Y. & Sadar, M. D. Enzalutamide and blocking androgen receptor in advanced prostate cancer: Lessons learnt from the history of drug development of antiandrogens. Res. Rep. Urol. 10, 23\u201332. https:\/\/doi.org\/10.2147\/RRU.S157116 (2018).","journal-title":"Res. Rep. Urol."},{"key":"43561_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.2174\/1389450118666170417144250","volume":"19","author":"X Chen","year":"2018","unstructured":"Chen, X., Lu, J., Xia, L. & Li, G. Drug resistance of enzalutamide in CRPC. Curr. Drug Targets 19, 613\u2013620. https:\/\/doi.org\/10.2174\/1389450118666170417144250 (2018).","journal-title":"Curr. Drug Targets"},{"key":"43561_CR24","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1158\/1535-7163.MCT-13-0027","volume":"12","author":"N Nadiminty","year":"2013","unstructured":"Nadiminty, N. et al. NF-kappaB2\/p52 induces resistance to enzalutamide in prostate cancer: Role of androgen receptor and its variants. Mol. Cancer Ther. 12, 1629\u20131637. https:\/\/doi.org\/10.1158\/1535-7163.MCT-13-0027 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"43561_CR25","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","volume":"371","author":"ES Antonarakis","year":"2014","unstructured":"Antonarakis, E. S. et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N. Engl. J. Med. 371, 1028\u20131038. https:\/\/doi.org\/10.1056\/NEJMoa1315815 (2014).","journal-title":"N. Engl. J. Med."},{"key":"43561_CR26","doi-asserted-by":"publisher","first-page":"815","DOI":"10.7150\/ijbs.7.815","volume":"7","author":"Z Guo","year":"2011","unstructured":"Guo, Z. & Qiu, Y. A new trick of an old molecule: Androgen receptor splice variants taking the stage?!. Int. J. Biol. Sci. 7, 815\u2013822. https:\/\/doi.org\/10.7150\/ijbs.7.815 (2011).","journal-title":"Int. J. Biol. Sci."},{"key":"43561_CR27","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/0008-5472.Can-08-3795","volume":"69","author":"ZY Guo","year":"2009","unstructured":"Guo, Z. Y. et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res. 69, 2305\u20132313. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-3795 (2009).","journal-title":"Cancer Res."},{"key":"43561_CR28","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.Can-08-2764","volume":"69","author":"R Hu","year":"2009","unstructured":"Hu, R. et al. Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer. Cancer Res. 69, 16\u201322. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-2764 (2009).","journal-title":"Cancer Res."},{"key":"43561_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22115515","author":"N Sobhani","year":"2021","unstructured":"Sobhani, N. et al. AR-V7 in metastatic prostate cancer: A strategy beyond redemption. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms22115515 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"43561_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/mnfr.202200146","volume":"66","author":"YC Koh","year":"2022","unstructured":"Koh, Y. C., Lin, S. J., Nagabhushanam, K., Ho, C. T. & Pan, M. H. The anti-obesity and anti-inflammatory capabilities of pterostilbene and its colonic metabolite pinostilbene protect against tight junction disruption from western diet feeding. Mol. Nutr. Food Res. 66, e2200146. https:\/\/doi.org\/10.1002\/mnfr.202200146 (2022).","journal-title":"Mol. Nutr. Food Res."},{"key":"43561_CR31","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/j.jnutbio.2009.02.004","volume":"21","author":"J Chao","year":"2010","unstructured":"Chao, J. et al. Protective effects of pinostilbene, a resveratrol methylated derivative, against 6-hydroxydopamine-induced neurotoxicity in SH-SY5Y cells. J. Nutr. Biochem. 21, 482\u2013489. https:\/\/doi.org\/10.1016\/j.jnutbio.2009.02.004 (2010).","journal-title":"J. Nutr. Biochem."},{"key":"43561_CR32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1002\/mnfr.200900143","volume":"54","author":"TT Wang","year":"2010","unstructured":"Wang, T. T., Schoene, N. W., Kim, Y. S., Mizuno, C. S. & Rimando, A. M. Differential effects of resveratrol and its naturally occurring methylether analogs on cell cycle and apoptosis in human androgen-responsive LNCaP cancer cells. Mol. Nutr. Food Res. 54, 335\u2013344. https:\/\/doi.org\/10.1002\/mnfr.200900143 (2010).","journal-title":"Mol. Nutr. Food Res."},{"key":"43561_CR33","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"O Trott","year":"2010","unstructured":"Trott, O. & Olson, A. J. AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31, 455\u2013461. https:\/\/doi.org\/10.1002\/jcc.21334 (2010).","journal-title":"J. Comput. Chem."},{"key":"43561_CR34","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1007\/978-1-4939-2269-7_19","volume":"1263","author":"S Dallakyan","year":"2015","unstructured":"Dallakyan, S. & Olson, A. J. Small-molecule library screening by docking with PyRx. Methods Mol. Biol. 1263, 243\u2013250. https:\/\/doi.org\/10.1007\/978-1-4939-2269-7_19 (2015).","journal-title":"Methods Mol. Biol."},{"key":"43561_CR35","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1110\/ps.051905906","volume":"15","author":"KP De Jesus-Tran","year":"2006","unstructured":"De Jesus-Tran, K. P. et al. Comparison of crystal structures of human androgen receptor ligand-binding domain complexed with various agonists reveals molecular determinants responsible for binding affinity. Protein Sci. 15, 987\u2013999. https:\/\/doi.org\/10.1110\/ps.051905906 (2006).","journal-title":"Protein Sci."},{"key":"43561_CR36","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0960-0760(00)00154-0","volume":"76","author":"F Claessens","year":"2001","unstructured":"Claessens, F. et al. Selective DNA binding by the androgen receptor as a mechanism for hormone-specific gene regulation. J. Steroid Biochem. 76, 23\u201330. https:\/\/doi.org\/10.1016\/S0960-0760(00)00154-0 (2001).","journal-title":"J. Steroid Biochem."},{"key":"43561_CR37","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1021\/bi961775g","volume":"36","author":"P Doesburg","year":"1997","unstructured":"Doesburg, P. et al. Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36, 1052\u20131064. https:\/\/doi.org\/10.1021\/bi961775g (1997).","journal-title":"Biochemistry"},{"key":"43561_CR38","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran, C. et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 324, 787\u2013790. https:\/\/doi.org\/10.1126\/science.1168175 (2009).","journal-title":"Science"},{"key":"43561_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/srep12007","author":"AM Moilanen","year":"2015","unstructured":"Moilanen, A. M. et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci. Rep. https:\/\/doi.org\/10.1038\/srep12007 (2015).","journal-title":"Sci. Rep."},{"key":"43561_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0923-1811(99)00091-2","volume":"23","author":"S Inui","year":"2000","unstructured":"Inui, S., Itami, S., Pan, H. J. & Chang, C. S. Lack of androgen receptor transcriptional activity in human keratinocytes. J. Dermatol. Sci. 23, 87\u201392. https:\/\/doi.org\/10.1016\/S0923-1811(99)00091-2 (2000).","journal-title":"J. Dermatol. Sci."},{"key":"43561_CR41","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/0008-5472.Can-08-0594","volume":"68","author":"SM Dehm","year":"2008","unstructured":"Dehm, S. M., Schmidt, L. J., Heemers, H. V., Vessella, R. L. & Tindall, D. J. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 68, 5469\u20135477. https:\/\/doi.org\/10.1158\/0008-5472.Can-08-0594 (2008).","journal-title":"Cancer Res."},{"key":"43561_CR42","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1158\/0008-5472.Can-12-3630","volume":"73","author":"YM Li","year":"2013","unstructured":"Li, Y. M. et al. Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines. Cancer Res. 73, 483\u2013489. https:\/\/doi.org\/10.1158\/0008-5472.Can-12-3630 (2013).","journal-title":"Cancer Res."},{"key":"43561_CR43","doi-asserted-by":"publisher","first-page":"S66","DOI":"10.1016\/j.juro.2006.06.071","volume":"176","author":"EJ Small","year":"2006","unstructured":"Small, E. J. & Ryan, C. J. The case for secondary hormonal therapies in the chemotherapy age. J. Urol. 176, S66-71. https:\/\/doi.org\/10.1016\/j.juro.2006.06.071 (2006).","journal-title":"J. Urol."},{"key":"43561_CR44","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1016\/S0140-6736(10)60172-9","volume":"375","author":"HI Scher","year":"2010","unstructured":"Scher, H. I. et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: A phase 1\u20132 study. Lancet 375, 1437\u20131446. https:\/\/doi.org\/10.1016\/S0140-6736(10)60172-9 (2010).","journal-title":"Lancet"},{"key":"43561_CR45","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/s41391-019-0182-x","volume":"23","author":"C De Nunzio","year":"2020","unstructured":"De Nunzio, C. et al. Adverse events related to abiraterone and enzalutamide treatment: Analysis of the EudraVigilance database and meta-analysis of registrational phase III studies. Prostate Cancer Prostatic Dis. 23, 199\u2013206. https:\/\/doi.org\/10.1038\/s41391-019-0182-x (2020).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"43561_CR46","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1038\/s41391-020-00275-3","volume":"24","author":"HY Lee","year":"2021","unstructured":"Lee, H. Y. et al. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: A systematic review with pairwise and network meta-analyses. Prostate Cancer Prostatic Dis. 24, 244\u2013252. https:\/\/doi.org\/10.1038\/s41391-020-00275-3 (2021).","journal-title":"Prostate Cancer Prostatic Dis."},{"key":"43561_CR47","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222413446","author":"YC Chung","year":"2021","unstructured":"Chung, Y. C. & Hyun, C. G. Inhibitory effects of pinostilbene on adipogenesis in 3T3-L1 adipocytes: A study of possible mechanisms. Int. J. Mol. Sci. https:\/\/doi.org\/10.3390\/ijms222413446 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"43561_CR48","doi-asserted-by":"publisher","first-page":"7947","DOI":"10.1074\/jbc.M109.092759","volume":"285","author":"WC Huang","year":"2010","unstructured":"Huang, W. C., Zhau, H. E. & Chung, L. W. Androgen receptor survival signaling is blocked by anti-beta2-microglobulin monoclonal antibody via a MAPK\/lipogenic pathway in human prostate cancer cells. J. Biol. Chem. 285, 7947\u20137956. https:\/\/doi.org\/10.1074\/jbc.M109.092759 (2010).","journal-title":"J. Biol. Chem."},{"key":"43561_CR49","doi-asserted-by":"publisher","first-page":"11623","DOI":"10.1093\/nar\/gkz1004","volume":"47","author":"L Duan","year":"2019","unstructured":"Duan, L. et al. Histone lysine demethylase KDM4B regulates the alternative splicing of the androgen receptor in response to androgen deprivation. Nucleic Acids Res. 47, 11623\u201311636. https:\/\/doi.org\/10.1093\/nar\/gkz1004 (2019).","journal-title":"Nucleic Acids Res."},{"key":"43561_CR50","doi-asserted-by":"publisher","first-page":"E4584","DOI":"10.1073\/pnas.1802415115","volume":"115","author":"L Fan","year":"2018","unstructured":"Fan, L. et al. Histone demethylase JMJD1A promotes alternative splicing of AR variant 7 (AR-V7) in prostate cancer cells. Proc. Natl. Acad. Sci. USA 115, E4584\u2013E4593. https:\/\/doi.org\/10.1073\/pnas.1802415115 (2018).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"43561_CR51","first-page":"3323","volume":"31","author":"L Kai","year":"2011","unstructured":"Kai, L. & Levenson, A. S. Combination of resveratrol and antiandrogen flutamide has synergistic effect on androgen receptor inhibition in prostate cancer cells. Anticancer Res. 31, 3323\u20133330 (2011).","journal-title":"Anticancer Res."},{"key":"43561_CR52","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1124\/dmd.104.000885","volume":"32","author":"T Walle","year":"2004","unstructured":"Walle, T., Hsieh, F., DeLegge, M. H., Oatis, J. E. Jr. & Walle, U. K. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos. 32, 1377\u20131382. https:\/\/doi.org\/10.1124\/dmd.104.000885 (2004).","journal-title":"Drug Metab. Dispos."},{"key":"43561_CR53","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1002\/1878-0261.12770","volume":"14","author":"Y Hirayama","year":"2020","unstructured":"Hirayama, Y., Tam, T., Jian, K., Andersen, R. J. & Sadar, M. D. Combination therapy with androgen receptor N-terminal domain antagonist EPI-7170 and enzalutamide yields synergistic activity in AR-V7-positive prostate cancer. Mol. Oncol. 14, 2455\u20132470. https:\/\/doi.org\/10.1002\/1878-0261.12770 (2020).","journal-title":"Mol. Oncol."},{"key":"43561_CR54","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/nmeth.2089","volume":"9","author":"CA Schneider","year":"2012","unstructured":"Schneider, C. A., Rasband, W. S. & Eliceiri, K. W. NIH Image to ImageJ: 25 years of image analysis. Nat. Methods 9, 671\u2013675. https:\/\/doi.org\/10.1038\/nmeth.2089 (2012).","journal-title":"Nat. Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43561-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43561-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43561-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T02:10:35Z","timestamp":1700273435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-43561-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,4]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["43561"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-43561-5","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,4]]},"assertion":[{"value":"1 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Some authors declare the following competing interests; the authors H.S.H. and J.K.W. are employed by Hesed Bio Corporation. Other authors S.W.S., K.T.K., and Y.C. declare that they do not have any competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16663"}}